A Multi-center Phase II Study with Safety Run-in Evaluating the Efficacy and Safety of Ublituximab in Combination with Ibrutinib in Patients with Select B-Cell Malignancies
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 13 Jun 2017
At a glance
- Drugs Ublituximab (Primary) ; Ibrutinib
- Indications B cell lymphoma; Chronic lymphocytic leukaemia; Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors TG Therapeutics Inc
- 13 Jun 2017 According to a TG Therapeutics Inc media release, data from the study will be presented at the 14th International Conference on Malignant Lymphoma.
- 05 Apr 2017 Planned End Date changed from 1 Mar 2017 to 1 Sep 2017.
- 05 Apr 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Aug 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History